课题基金 / 基金详情

MULTICENTER PHASE 3 TRIAL OF DAB3891L-2 IN CTCL PATIENTS IN STAGE IA-IVA DISEASE

MULTICENTER PHASE 3 TRIAL OF DAB3891L-2 IN CTCL PATIENTS IN STAGE IA-IVA DISEASE
DAB3891L-2 在 IA-IVA 期 CTCL 患者中的多中心 3 期试验
批准号：
6245687
负责人：
BRIAN JEGASOTHY
金额：
$1.76万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-03-18 至 1997-11-30
来源：
https://reporter.nih.gov/project-details/6245687
关键词：
clinical research human subject human therapy evaluation immunoconjugates interleukin 2 mycosis fungoides lymphoma neoplasm /cancer immunotherapy

项目摘要

项目成果

BRIAN JEGASOTHY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DAV389IL-2 is a targeted cytotoxin produced by recombinant DNA techniques. Action occurs as a result of binding to and subsequent internalization by IL-2R expression on lymphoma cells. This is a phase III open-label study for Cutaneous T-Cell Lymphoma (CTCL) patients with stage Ia-IVad disease previously in 950755 or 950756. Treatment will be a 15 minute IV infusion of DAB389IL-2 for 5 days every 21 days for 8 courses.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHASE III RANDOMIZED TRIAL OF TWO DOSE DA389IL-2 IN CTCL <3 PREVIOUS TREATMENTS
PHASE I STUDY OF BMS-188667 IN PATIENTS WITH PSORIASIS VULGARIS
MULTICENTER PHASE 3 TRIAL OF DAB3891L-2 IN CTCL PATIENTS IN STAGE IA-IVA DISEASE
PHASE III RANDOMIZED TRIAL OF TWO DOSE DA389IL-2 IN CTCL <3 PREVIOUS TREATMENTS
海外基金